Alphatec (NASDAQ:ATEC) Hits New 52-Week Low After Earnings Miss

Alphatec Holdings, Inc. (NASDAQ:ATEC) hit a new 52-week low on Wednesday after the company announced weaker than expected quarterly earnings. The company traded as low as $6.85 and last traded at $7.0710, with a volume of 2676831 shares traded. The stock had previously closed at $10.23.

The medical technology company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.21). The firm had revenue of $192.11 million during the quarter, compared to analyst estimates of $197.51 million. The firm’s revenue was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.35) EPS.

Alphatec News Roundup

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: Company re‑affirmed an ambitious FY‑2026 outlook — management is forecasting roughly $882M in 2026 revenue and $134M in adjusted EBITDA, which supports a longer‑term growth thesis if execution continues. MSN: Forecasts
• Positive Sentiment: Alphatec reported robust gross margins (GAAP ~71%, non‑GAAP ~72%) and year‑over‑year revenue growth (~13.6%), and provided investor materials and a slide deck highlighting operating improvements — these metrics help justify valuation if revenue momentum persists. BusinessWire: Q1 Results
• Positive Sentiment: Liquidity strengthened: Alphatec established a new senior secured syndicated credit facility, which reduces near‑term financing risk and supports growth investments. TipRanks: Credit Facility
• Neutral Sentiment: Earnings call transcript and investor presentation are available for detailed read‑throughs of product adoption, reimbursement commentary and margin drivers — useful for due diligence but not new headline news. Seeking Alpha: Call Transcript
• Negative Sentiment: Institutional selling: a fund disclosed ~$$18M of Alphatec sales last quarter and the stock plunged after the earnings release — large redemptions or reallocations can pressure the stock near term. Fool: Fund Selling
• Negative Sentiment: Mixed / missed results: reported Q1 EPS and revenue came in below some consensus figures (EPS hurt by reported miss vs. consensus), which triggered the immediate selloff and highlights execution risk against street expectations. MarketBeat: Earnings Recap
• Negative Sentiment: Analyst target reduced: Needham cut its price target from $25 to $14 (while keeping a buy rating), trimming upside assumptions and signaling more conservative near‑term expectations from some sell‑side firms. Benzinga: PT Cut

Analyst Upgrades and Downgrades

Several analysts recently commented on ATEC shares. HC Wainwright reaffirmed a “buy” rating and set a $24.00 price objective on shares of Alphatec in a research note on Monday, January 12th. Needham & Company LLC dropped their price objective on Alphatec from $25.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday. Stifel Nicolaus dropped their price objective on Alphatec from $24.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, March 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alphatec in a research note on Friday, March 27th. Finally, Canaccord Genuity Group set a $23.00 price objective on Alphatec in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.64.

Insider Transactions at Alphatec

In other Alphatec news, EVP Craig E. Hunsaker sold 82,765 shares of Alphatec stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $12.45, for a total value of $1,030,424.25. Following the sale, the executive vice president owned 1,726,209 shares of the company’s stock, valued at $21,491,302.05. This trade represents a 4.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Scott Lish sold 260,535 shares of Alphatec stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $12.30, for a total value of $3,204,580.50. Following the completion of the sale, the chief operating officer directly owned 815,704 shares in the company, valued at $10,033,159.20. This represents a 24.21% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 689,614 shares of company stock worth $8,634,850. Company insiders own 22.80% of the company’s stock.

Institutional Trading of Alphatec

A number of hedge funds and other institutional investors have recently modified their holdings of ATEC. Summit Securities Group LLC acquired a new stake in shares of Alphatec in the first quarter valued at about $29,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Alphatec in the third quarter valued at about $34,000. Osterweis Capital Management Inc. acquired a new stake in shares of Alphatec in the second quarter valued at about $37,000. Northwestern Mutual Wealth Management Co. increased its position in shares of Alphatec by 157.1% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,571 shares of the medical technology company’s stock valued at $54,000 after acquiring an additional 1,571 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in shares of Alphatec in the third quarter valued at about $73,000. Institutional investors and hedge funds own 66.35% of the company’s stock.

Alphatec Trading Down 30.8%

The company has a debt-to-equity ratio of 40.35, a current ratio of 2.06 and a quick ratio of 1.28. The business has a 50-day moving average of $11.73 and a 200-day moving average of $15.95. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of -7.53 and a beta of 0.96.

About Alphatec

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.